AH036 - The Rise of GLP-1s & Partnering to Manage Chronic Diseases, with Vida Health

In this episode of the Astonishing Healthcare podcast, Joe Murad, CEO of Vida Health, joins host Justin Venneri and Capital Rx Chief Clinical Officer Sara Izadi, PharmD, in the studio for a discussion about glucagon-like peptide-1 (of GLP-1) medications and how partnering to manage cardiometabolic health can help plan sponsors control costs and keep their populations healthy. Joe and Sara review the latest data, including the rising prevalence of obesity and diabetes, GLP-1 discontinuation rates, the robust GLP-1 pipeline, and they highlight the innovative partnership between Capital Rx and Vida. Together, they explore the importance of appropriate patient management, education, and support, nuances of GLP-1 prescribing like dose titration, the role of digital health technology in achieving effective healthcare outcomes and coordinating care with other providers, and what to watch for in 2025.Related ContentHow to Manage Pharmacy Benefit Spend in a GLP-1 WorldAH021 - Managing Pharmacy Costs in a GLP-1 World, with Bridget MulvennaGLP-1s are No Laughing MatterSourcesHow many adults with private health insurance could use GLP-1 drugs (KFF; 9/5)GLP-1 Receptor Agonist Discontinuation Among Patients With Obesity and/or Type 2 Diabetes (JAMA; 5/24)Poll: 1 in 8 Adults Say They’ve Taken a GLP-1 Drug, Including 4 in 10 of Those with Diabetes and 1 in 4 of Those with Heart Disease (KFF; 5/10)The Use of Medicines in the U.S. 2024: Usage and Spending Trends and Outlook to 2028 (IQVIA; 5/7)For more information about Capital Rx and this episode, please visit Capital Rx Insights.